Amicus Therapeutics Overview

  • Founded
  • 2002

Founded
  • Status
  • Public

  • Employees
  • 496

Employees
  • Stock Symbol
  • FOLD

Stock Symbol
  • Investments
  • 4

  • Share Price
  • $12.06

  • (As of Thursday Closing)

Amicus Therapeutics General Information

Description

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 3675 Market Street
  • Philadelphia, PA 19104
  • United States
+1 (215) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amicus Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.06 $12.73 $5.91 - $12.76 $3.57B 280M 3.42M -$0.99

Amicus Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 3,056,664 3,100,708 5,948,465 2,172,957
Revenue 321,145 305,514 260,886 182,237
EBITDA (235,736) (203,383) (246,209) (342,512)
Net Income (280,988) (250,460) (276,852) (356,388)
Total Assets 800,589 905,140 886,520 850,207
Total Debt 451,039 440,129 441,730 210,225
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amicus Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amicus Therapeutics‘s full profile, request access.

Request a free trial

Amicus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Amicus Therapeutics‘s full profile, request access.

Request a free trial

Amicus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for peopl
Pharmaceuticals
Philadelphia, PA
496 As of 2021
00000
00000000 00000

000000

a commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000

000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000000000000
Allschwil, Switzerland
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amicus Therapeutics Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astria Therapeutics Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 0000000000 Corporate Backed or Acquired Allschwil, Switzerland 0000 00.000 00000000 00.000
0000000 Formerly VC-backed Leiden, Netherlands 0000 000000&0
0000000 0000000 Corporate Backed or Acquired Pittsburgh, PA 000 00000 00000000 00000
0000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
You’re viewing 5 of 20 competitors. Get the full list »

Amicus Therapeutics Patents

Amicus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210251972-A1 Methods of treating fabry disease Pending 10-Feb-2020 000000000
JP-2021024864-A Method of treating fabry disease in patient having a mutation in the gla gene Pending 07-Aug-2019 00000000000
EP-3851105-A3 Methods of treating fabry disease in patients having a mutation in the gla gene Pending 07-Aug-2019 00000000000 0
EP-3851105-A2 Methods of treating fabry disease in patients having a mutation in the gla gene Pending 07-Aug-2019 000000000 0
EP-3895708-A2 Methods of treating fabry disease in patients having a mutation in the gla gene Pending 07-Aug-2019 G16B20/00 0
To view Amicus Therapeutics’s complete patent history, request access »

Amicus Therapeutics Executive Team (20)

Name Title Board Seat Contact Info
Daphne Quimi Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Bradley Campbell President & Chief Executive Officer
Jeff Castelli Ph.D Chief Development Officer
Andrew Faughnan Director, Investor Relations
Patrik Florencio Senior Vice President & Global Chief Compliance & Risk Officer
You’re viewing 5 of 20 executive team members. Get the full list »

Amicus Therapeutics Board Members (19)

Name Representing Role Since
Bradley Campbell Amicus Therapeutics President & Chief Executive Officer 000 0000
Burke Whitman Amicus Therapeutics Board Member 000 0000
Craig Wheeler Amicus Therapeutics Board Member 000 0000
Eiry Roberts MD Self Board Member 000 0000
Glenn Sblendorio Self Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Amicus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amicus Therapeutics Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 20-Sep-2018 0000000000 00000 Biotechnology 0000 0000
000000 05-Jul-2016 0000000000 000.00 Biotechnology 0000 0000
00000000 30-Sep-2015 0000000000 00000 Pharmaceuticals 0000 0000
Callidus Biopharma 21-Nov-2013 Merger/Acquisition 0000 Drug Delivery 0000 0000
To view Amicus Therapeutics’s complete acquisitions history, request access »